New Clinical Study Publication Validates Respiratory Outcomes for the Onera Home-polysomnography System
Onera Health, a leader in transforming sleep medicine, announces the recent publication of a multicenter validation study of its Onera Sleep Test System (STS) in the ERJ Open Research, a leading, fully open-access scientific journal published by the European Respiratory Society (ERS). This is the second publication from this study, and it demonstrates that the patch-based Onera STS home-polysomnography (hPSG) device accurately identifies respiratory events and distinguishes AHI severity when validated against simultaneous in-lab polysomnography and is a viable option for unattended home use.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112821647/en/
Patient sleeps with the patient-applied Onera home Polysomnography (Onera hPSG) solution.
The international multicenter study was managed by an independent Clinical Research Organization and involved the analysis of 206 participants across seven clinical sites in Germany and a US-based core laboratory at Johns Hopkins University. As detailed in the first publication, the study found high concordance between the Onera STS and traditional PSG across essential sleep variables and key respiratory parameters, as well as substantial epoch-by-epoch agreement in sleep staging and comparable inter-scorer reliability between the two systems, which is essential for physicians to make accurate diagnoses and treatment decisions in sleep medicine. This publication extends those findings to include accurately identifying respiratory events and distinguishing AHI severity when validated against simultaneous in-lab polysomnography, further validating the Onera STS as a viable option for unattended home use.
"We are very pleased to have further validation of the utility of Onera STS in accurately identifying respiratory events and distinguishing AHI severity,” said Ruben de Francisco, Founder and CEO of Onera Health. "This comprehensive validation study further demonstrates that our innovative, patch-based technology can deliver the level of accuracy needed for a comprehensive hPSG sleep test, with an accuracy that is equivalent to that of traditional in-lab PSG for all relevant clinical parameters. This publication further supports our mission to make the gold-standard sleep test, polysomnography or PSG, available at the patient’s home.”
"These additional results from the Onera STS validation study further demonstrate the diagnostic value of high-quality sleep assessment in the patient's natural environment. The ability to achieve results from home PSG testing that are equivalent to in-lab PSG will help remove the barriers to access created by resource limitations thus providing accurate diagnosis to significantly more patients suffering from under or undiagnosed sleep disorders,” added Dr. David P. White, Harvard Medical School, Boston, United States, and Member of the Medical Advisory Board at Onera Health.
This landmark validation study is part of Onera Health's comprehensive clinical evidence generation program, demonstrating the commitment to rigorous scientific validation of Onera’s technology. Additional studies are currently ongoing across multiple centers and healthcare settings, which will further validate the clinical utility and real-world impact of Onera’s home Polysomnography solution. This evidence generation strategy reflects Onera’s dedication to advancing sleep medicine through high-quality clinical research.
This study publication, entitled 'Clinical validation of respiratory outcomes for a patch-based polysomnography system', is published in the ERJ Open Research journal published by the European Respiratory Society (ERS) and can be accessed online at https://publications.ersnet.org/content/erjor/early/2025/12/04/2312054100857-2025https://doi.org/10.1183/23120541.00857-2025.
The first publication from this study entitled 'Clinical validation of a wireless patch-based polysomnography system', was published in the Journal of Clinical Sleep Medicine and can be accessed online at https://doi.org/10.5664/jcsm.11524
About Onera
Onera Health is a leader in transforming sleep medicine and remote monitoring. Their breakthrough diagnostic solutions and services are poised to help millions of people struggling with sleep-related ailments while also impacting other medical fields by monitoring various chronic conditions, ultimately improving the health and quality of life of patients worldwide. The company’s innovative solutions provide comprehensive sleep test data to physicians in a variety of clinical and non-clinical environments to optimize patient care and reduce healthcare costs. Onera has offices in the Netherlands and the U.S. For more information, go to onerahealth.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20260112821647/en/
Contacts
For additional information or media inquiries, please contact:
Swea Ann Hagenhoff
Sr. Branding and Communications Specialist
Onera Health
media@onerahealth.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HumanX Amsterdam Reveals First 100 Speakers, Bringing Global AI Powerhouses to Europe13.1.2026 14:00:00 CET | Press Release
HumanX, the global AI summit for executives and innovators, today unveiled its first 100 speakers and opened registration for HumanX Amsterdam, taking place 22–24 September 2026 at The RAI. Built by the team behind Money20/20, Shoptalk, and HLTH, HumanX Amsterdam brings the proven formula of its #1 U.S. flagship event and ecosystem gathering to Europe. The event convenes over 2,500 senior leaders focused on moving beyond the hype to drive practical, responsible AI implementation across industries. Speakers Leading the Conversation The first 100 speakers include AI company founders such as Anton Osika (Lovable), Jan Oberhauser (n8n), May Habib (Writer), Arvind Jain (Glean), and Jarek Kutylowski (DeepL), alongside executives scaling AI in the enterprise, including Clay Bavor (Sierra), Des Traynor (Intercom), and Eléonore Crespo (Pigment), and senior leaders from global brands like Diageo, Disney, and Replit. Additional speakers represent over 20 AI unicorns, including Quantexa, Owkin, an
GARDP and Debiopharm Partner to Advance Development of Novel Gonorrhea Drug13.1.2026 14:00:00 CET | Press Release
The GARDP Foundation (known as GARDP) and the privately-owned, global biopharmaceutical company Debiopharm today announced that they have entered into a collaboration and license agreement to pursue the development of Debio1453, a novel, first-in-class antibiotic targeting Neisseria gonorrhoeae. With 82 million new cases each year, and the continued spread of multidrug-resistant N. gonorrhoeae strains, gonorrhea represents a global health crisis. This new partnership will help ensure that gonorrhea continues to be a treatable disease and will alleviate the risk of the emergence of future resistance, by ensuring that the antibiotic pipeline continues to be replenished. Gonorrhea caused by N. gonorrhoeae is currently in danger of becoming untreatable because of antimicrobial resistance (AMR). Having developed resistance to almost all antibiotics used to treat it, only one last recommended treatment, ceftriaxone, remains effective, and now we are seeing a growing number of cases that are
Wolfspeed Achieves 300mm Silicon Carbide (SiC) Technology Breakthrough13.1.2026 14:00:00 CET | Press Release
Wolfspeed, Inc. (NYSE: WOLF), a global leader in silicon carbide technology, today announced a significant industry milestone with the successful production of a single crystal 300mm (12-inch) silicon carbide wafer. Backed by one of the industry’s largest and foundational silicon carbide IP portfolios, comprising more than 2,300 issued and pending patents worldwide, Wolfspeed is pioneering the transition to 300mm technology, establishing a clear path to future volume commercialization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260113487095/en/ Wolfspeed produces 300mm silicon carbide wafer. This technology advancement represents a major step forward for next-generation computing platforms, immersive AR/VR systems, and high-efficiency, advanced power devices. By expanding silicon carbide to 300mm, Wolfspeed is unlocking new performance thresholds and manufacturing scalability for some of the world’s most demanding semico
ExaGrid’s FY 2025 Results—A Record Quarter and a Record Year for Company13.1.2026 14:00:00 CET | Press Release
ExaGrid®, the industry’s only Tiered Backup Storage solution with AI-Powered Retention Time-Lock (RTL) that includes a non-network-facing tier (tiered air gap), Auto Detect & Guard, delayed deletes and immutability for ransomware recovery, today announced that it had record bookings and record revenue in the fourth quarter ending December 31, 2025, and had a record-year for bookings and revenue for 2025. ExaGrid broke many records in the quarter (Q4 2025), including: Record overall revenue and bookings Record revenue and bookings for new customers Record revenue and bookings for existing customer repeat orders Record 202 new logo customers in the quarter Record 88 six-figure new logo customers 3 seven-figure new logo customer deals In addition, ExaGrid had a record bookings and revenue year in 2025 and remained P&L, EBITDA, and free cash flow positive for the 20th consecutive quarter. The company is 100% debt-free, demonstrating strong financial health as a company. ExaGrid added 202 n
Armis Secures Italy’s Primary Public Healthcare Provider for the City of Naples as Cyber Threats Increase13.1.2026 14:00:00 CET | Press Release
Armis, the cyber exposure management & security company, today announced that ASL Napoli 1 Centro, Italy’s primary public healthcare provider for the City of Naples, is securing its attack surface using Armis Centrix™, the Armis Cyber Exposure Management Platform. Prior to working with Armis, ASL Napoli 1 Centro did not have the tools or capabilities to monitor physical and virtual assets in real time, which posed a challenge for its security and compliance. Armis Centrix™ was deployed with a clear goal: to provide ASL Napoli 1 Centro with a comprehensive, real-time view of its connected biomedical inventory and the associated risks to the overall environment. “Time-to-value was practically immediate; Armis began delivering valuable information as soon as the system was activated and connected to our internal network,” said Fulvio Paone, Director of the ICT and Digital Transformation Unit at ASL Napoli 1 Centro. “Armis has given us visibility into a critical area. This isn’t just about
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom